The BioPharm Brief: Deals, Data, and a $2 Billion Bet

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping the biopharmaceutical industry.

Here’s what we have today.

First, Novo Nordisk is adding another oral obesity candidate to its pipeline. The company has licensed global rights outside Greater China to Hengrui Pharma’s HRS-1596, a phase 1-ready GLP-1/GIP dual agonist designed for potentially once-weekly oral dosing. Novo will pay $300 million upfront, with the deal worth up to $2.6 billion in development, regulatory, and commercial milestones, plus royalties. Hengrui has received approval in China to begin phase 1 trials in obesity and type 2 diabetes, although no clinical data have been reported yet.

In Huntington’s disease, uniQure has reported 48-month data for AMT-130. The gene therapy continued to show slowing of disease progression over four years, but the primary endpoint did not reach statistical significance. The company submitted a BLA to FDA earlier this month under the accelerated approval pathway and requested priority review.

And AstraZeneca is putting $2 billion behind Summit Therapeutics and its cancer program. The investment gives AstraZeneca roughly a 12% stake in Summit and comes with a clinical collaboration to test Summit’s PD-1/VEGF bispecific ivonescimab in combination with AstraZeneca ADCs, including the claudin-18.2-targeted sonesitatug vedotin. The companies plan to begin combination trials in gastrointestinal cancers.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit www.BioPharmInternational.com.

Key takeaways

• Novo is betting on the next wave of oral GLP-1s, licensing a once-weekly candidate from Hengrui in a deal worth up to $2.6 billion.
• AMT-130 continues to show a signal in Huntington’s disease, but its primary endpoint still missed statistical significance at 48 months.
• AstraZeneca is putting serious money behind an ADC and bispecific combination strategy, investing $2 billion in Summit and its ivonescimab program.